GI Oncology

Advertisement
Brandon TwyfordColorectal Cancer | January 28, 2025
The study showed that favezelimab/pembrolizumab did not demonstrate a survival benefit over SOC.
Read More
Boris Pasche, MD, PhDLiver Cancer | January 28, 2025
Dr. Pasche discusses the trial that led to the TheraBionic P1 device's regulatory approval by the FDA.
Shubham Pant, MDPancreatic Cancer | January 27, 2025
Dr. Pant shared updates on a phase 1b dose escalation trial of gemcitabine, nab-paclitaxel, and lixumistat.
Shubham Pant, MDBile Duct Cancer | January 27, 2025
Dr. Pant offered insights on the key findings of zanidatamab's efficacy and safety in HER2-positive BTC.
Benjamin Weinberg, MD, FACPLiver Cancer | January 27, 2025
Dr. Weinberg provided his perspective on the CheckMate 9DW expanded analyses, as well as multiple studies in CRC.
Tsuyoshi Shirakawa, MD, PhDPancreatic Cancer | January 27, 2025
Dr. Shirakawa highlighted the results of the NAPOLEON-2 trial, including how RWD compare to clinical trial findings.
Efrat Dotan, MDPancreatic Cancer | January 27, 2025
Dr. Dotan shared the effects of baseline geriatric and QOL assessments on outcomes for older patients with pancreatic cancer.
Maen Abdelrahim, MD, PhDPancreatic Cancer | January 27, 2025
Dr. Abdelrahim details the impact of UGT1A1*28 polymorphism on tolerability in patients with mPDAC in the NAPOLI 3 study.
Emily MenendezLiver Cancer | January 24, 2025
Previous data pointed to the benefit of adjuvant immunotherapy for patients with HCC through the use of CIK cells.
Emily MenendezColorectal Cancer | January 24, 2025
Previously presented results of the trial showed favorable PFS rates in the m-FOLFOXIRI and cetuximab arm.
Christopher Lieu, MDLiver Cancer | January 24, 2025
Dr. Lieu details practice-changing studies from ASCO GI 2025, including CheckMate-9DW, CheckMate 8HW, and BREAKWATER.
Emily MenendezGEP-NETs | January 24, 2025
The combination of EVE/LAN can significantly prolong PFS in patients with well-differentiated grade 1/2 GEP-NETs.
Emily MenendezGastric Cancer | January 23, 2025
ASPEN-06 analyzed the CD47 myeloid checkpoint inhibitor ALX148 in patients with HER2-overexpressing gastric cancer.
Emily MenendezLiver Cancer | January 23, 2025
In EMERALD-1, investigators analyzed the combination of durvalumab plus bevacizumab and TACE versus placebo with TACE.
Zachary BessetteLiver Cancer | January 23, 2025
Additional analyses from the CheckMate 9DW study shed further light on the clinical efficacy and safety of ipi/nivo for uHCC.
Zachary BessetteBile Duct Cancer | January 23, 2025
Results of NIR-B trial sheds light on the clinical utility of niraparib in patients with BRCA-mutated GI cancers.
Zachary BessetteGEP-NETs | January 23, 2025
A novel auto-segmentation model and radiomics signature may help with preoperative clinical decision-making for GEP-NETs.
Brandon TwyfordLiver Cancer | January 23, 2025
The study reinforces the potential of triplet blockade with casdozo, atezo, and bev as a viable approach for managing uHCC.
Brandon TwyfordColorectal Cancer | January 23, 2025
The study shows the prognostic value of ctDNA in detecting MRD in patients with stage II/III CRC.
Richard S. Finn, MDLiver Cancer | January 24, 2025
Dr. Finn previews key abstracts in liver cancer and other hepatobiliary malignancies from ASCO GI 2025.
Advertisement
Advertisement
Advertisement
Latest News

January 28, 2025